Supporting the possibility that NF-kB may upregulate p53 is the finding that an elevated expression of miR18a in GC cells represses IRF2 (interferon response factor 2), an activator of NF-kB [330], decreasing the p53 protein levels, leading to higher cell motility and correlating with a poor prognosis [331]. Here, NFKB1 is linked to gastric cancer.